Ordering Recommendation

Use to monitor treatment of individuals with classic or nonclassic congenital adrenal hyperplasia.

Mnemonic
CAH RX PANEL
Methodology

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Collect between 6-10 a.m.

Collect

Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA).

Specimen Preparation

Transfer 1.2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.7 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions
Remarks
Stability

Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months

Reference Interval
Test Number
Components
Reference Interval
2001638 Androstenedione Effective August 19, 2013
Age Female Male
Premature Infants, 26-28 weeks-Day 4 0.92-2.82 ng/mL 0.92-2.82 ng/mL
Premature Infants, 31-35 weeks-Day 4 0.80-4.46 ng/mL 0.80-4.46 ng/mL
Full-term Infants, 1-7 days 0.20-2.90 ng/mL 0.20-2.90 ng/mL
8-30 days 0.18-0.80 ng/mL 0.18-0.80 ng/mL
1-5 months 0.06-0.68 ng/mL 0.06-0.68 ng/mL
6-24 months Less than 0.15 ng/mL 0.03-0.15 ng/mL
2-3 years Less than 0.16 ng/mL Less than 0.11 ng/mL
4-5 years 0.02-0.21 ng/mL 0.02-0.17 ng/mL
6-7 years 0.02-0.28 ng/mL 0.01-0.29 ng/mL
8-9 years 0.04-0.42 ng/mL 0.03-0.30 ng/mL
10-11 years 0.09-1.23 ng/mL 0.07-0.39 ng/mL
12-13 years 0.24-1.73 ng/mL 0.10-0.64 ng/mL
14-15 years 0.39-2.00 ng/mL 0.18-0.94 ng/mL
16-17 years 0.35-2.12 ng/mL 0.30-1.13 ng/mL
18-39 years 0.26-2.14 ng/mL 0.33-1.34 ng/mL
40 years and older 0.13-0.82 ng/mL 0.23-0.89 ng/mL
Pre-menopausal 0.26-2.14 ng/mL Does Not Apply
Postmenopausal 0.13-0.82 ng/mL Does Not Apply
Tanner Stage I 0.05-0.51 ng/mL 0.04-0.32 ng/mL
Tanner Stage II 0.15-1.37 ng/mL 0.08-0.48 ng/mL
Tanner Stage III 0.37-2.24 ng/mL 0.14-0.87 ng/mL
Tanner Stage IV-V 0.35-2.05 ng/mL 0.27-1.07 ng/mL

0092332 17-Hydroxyprogesterone Quantitative by HPLC-MS/MS, Serum or Plasma Effective August 19, 2013
Age
Female
Male
Premature (26-28 weeks) 124-841 ng/dL 124-841 ng/dL
Premature (29-35 weeks) 26-568 ng/dL 26-568 ng/dL
Full term Day 3 7-77 ng/dL 7-77 ng/dL
4 days-30 days 7-106 ng/dL Less than 200 ng/dL
1 month-2 months 13-106 ng/dL Less than 200 ng/dL
3 months-5 months 13-106 ng/dL 3-90 ng/dL
6  months-1 year Less than or equal to 148 ng/dL Less than or equal to 148 ng/dL
2-3 years Less than or equal to 256 ng/dL Less than or equal to 228 ng/dL
4-6 years Less than or equal to 299 ng/dL Less than or equal to 208 ng/dL
7-9 years Less than or equal to 71 ng/dL Less than or equal to 63 ng/dL
10-12 years Less than or equal to 129 ng/dL Less than or equal to 79 ng/dL
13-15 years 9-208 ng/dL 9-140 ng/dL
16-17 years Less than or equal to 178 ng/dL 24-192 ng/dL
18 years and older Less than 207 ng/dL Less than 139 ng/dL
Follicular 15-70 ng/dL Does Not Apply
Luteal 35-290 ng/dL Does Not Apply
Tanner Stage I Less than or equal to 74 ng/dL Less than or equal to 62 ng/dL
Tanner Stage II Less than or equal to 164 ng/dL Less than or equal to 104 ng/dL
Tanner Stage III 13-209 ng/dL Less than or equal to 151 ng/dL
Tanner Stage IV-V 7-170 ng/dL 20-173 ng/dL

0081058 Testosterone, Females or Children Effective August 19, 2013
Age
Female
Male
Premature (26-28 weeks) 5-16 ng/dL 59-125 ng/dL
Premature (31-35 weeks) 5-22 ng/dL 37-198 ng/dL
Newborn 20-64 ng/dL 75-400 ng/dL
1-5 months Less than 20 ng/dL 14-363 ng/dL
6-24 months Less than 9 ng/dL Less than 37 ng/dL
2-3 years Less than 20 ng/dL Less than 15 ng/dL
4-5 years Less than 30 ng/dL Less than 19 ng/dL
6-7 years Less than 7 ng/dL Less than 13 ng/dL
8-9 years 1-11ng/dL 2-8 ng/dL
10-11 years 3-32 ng/dL 2-165 ng/dL
12-13 years 6-50 ng/dL 3-619 ng/dL
14-15 years 6-52 ng/dL 31-733 ng/dL
16-17 years 9-58 ng/dL 158-826 ng/dL
18-39 years 9-55 ng/dL 300-1080 ng/dL
40-59 years 9-55 ng/dL 300-890 ng/dL
60 years and older 5-32 ng/dL 300-720 ng/dL
Premenopausal (18 years and older) 9-55 ng/dL Does Not Apply
Postmenopausal 5-32 ng/dL Does Not Apply
Tanner Stage I 2-17 ng/dL 2-15 ng/dL
Tanner Stage II 5-40 ng/dL 3-303 ng/dL
Tanner Stage III 10-63 ng/dL 10-851 ng/dL
Tanner Stage IV-V 11-62 ng/dL 162-847 ng/dL

Interpretive Data

Total testosterone values may not reflect optimal concentrations in all individuals. Free or bioavailable testosterone measurements may provide supportive information.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

82157; 83498; 84403

Components
Component Test Code* Component Chart Name LOINC
0081058 Testosterone, LC-MS/MS 2986-8
0092332 17-Hydroxyprogesterone, HPLC-MS/MS 1668-3
2001639 Androstenedione by TMS 1854-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • 17-Hydroxyprogesterone (Congenital Adrenal Hyperplasia Treatment Panel)
  • Androstenedione (Congenital Adrenal Hyperplasia Treatment Panel)
  • Testosterone (Congenital Adrenal Hyperplasia Treatment Panel)
Congenital Adrenal Hyperplasia Treatment Panel